The American Journal of Surgical Pathology, ISSN 0147-5185, 03/2019, Volume 43, Issue 3, pp. 432 - 433
Journal Article
Oncotarget, ISSN 1949-2553, 10/2017, Volume 8, Issue 49, pp. 85214 - 85223
MISIIR is a potential target for ovarian cancer (OC) therapy due to its tissue-specific pattern of expression. 3C23K is a novel therapeutic monoclonal...
Mullerian inhibiting substance receptor | Targeted therapy | 3C23K | Ovarian cancer | Patient-derived xenograft | targeted therapy | XENOGRAFT MODELS | ovarian cancer | MULLERIAN-INHIBITING SUBSTANCE | OVARIAN-CANCER | CELL-LINES | mullerian inhibiting substance receptor | TUMOR-MODELS | CELL BIOLOGY | HORMONE | THERAPY | patient-derived xenograft | IMMUNOTHERAPY | II RECEPTOR | MICE
Mullerian inhibiting substance receptor | Targeted therapy | 3C23K | Ovarian cancer | Patient-derived xenograft | targeted therapy | XENOGRAFT MODELS | ovarian cancer | MULLERIAN-INHIBITING SUBSTANCE | OVARIAN-CANCER | CELL-LINES | mullerian inhibiting substance receptor | TUMOR-MODELS | CELL BIOLOGY | HORMONE | THERAPY | patient-derived xenograft | IMMUNOTHERAPY | II RECEPTOR | MICE
Journal Article
Genes and Cancer, ISSN 1947-6019, 05/2017, Volume 8, Issue 5-6, pp. 589 - 599
Limited effectiveness of therapeutic agents targeting epidermal growth factor receptor (EGFR) in clinical trials using unselected ovarian cancer patients has...
Tissue microarray | EGFR | Epidermal growth factor receptor | Ovarian cancer | Prognostic biomarker | prognostic biomarker | Research Paper | ovarian cancer | tissue microarray | epidermal growth factor receptor
Tissue microarray | EGFR | Epidermal growth factor receptor | Ovarian cancer | Prognostic biomarker | prognostic biomarker | Research Paper | ovarian cancer | tissue microarray | epidermal growth factor receptor
Journal Article
Lancet Oncology, The, ISSN 1470-2045, 2013, Volume 14, Issue 9, pp. 853 - 862
Summary Background Few biomarkers of ovarian cancer prognosis have been established, partly because subtype-specific associations might be obscured in studies...
Hematology, Oncology and Palliative Medicine | BREAST-CANCER | CELL-TYPE | 1 MESSENGER-RNA | ONCOLOGY | FAVORABLE PROGNOSIS | SEROUS CARCINOMA | RISK | PROGESTERONE-RECEPTOR | GROWTH-FACTOR | ESTROGEN-RECEPTOR | EPITHELIAL OVARIAN | Receptors, Estrogen - metabolism | Prognosis | Follow-Up Studies | Adenocarcinoma, Mucinous - pathology | Tissue Array Analysis | Adenocarcinoma, Clear Cell - mortality | Humans | Middle Aged | Cystadenocarcinoma, Serous - metabolism | Ovarian Neoplasms - pathology | Ovarian Neoplasms - mortality | Cystadenocarcinoma, Serous - pathology | Case-Control Studies | Immunoenzyme Techniques | Carcinoma, Endometrioid - metabolism | Receptors, Progesterone - metabolism | Neoplasm Grading | Biomarkers, Tumor - metabolism | Female | Ovarian Neoplasms - metabolism | Ovary - metabolism | Ovary - pathology | Adenocarcinoma, Clear Cell - metabolism | Neoplasm Invasiveness | Survival Rate | Adenocarcinoma, Mucinous - mortality | Carcinoma, Endometrioid - mortality | Adenocarcinoma, Mucinous - metabolism | Cystadenocarcinoma, Serous - mortality | Adenocarcinoma, Clear Cell - pathology | Neoplasm Staging | Carcinoma, Endometrioid - pathology | Consortia | Analysis | Oncology, Experimental | Hormones | Research | Ovarian cancer | Cancer
Hematology, Oncology and Palliative Medicine | BREAST-CANCER | CELL-TYPE | 1 MESSENGER-RNA | ONCOLOGY | FAVORABLE PROGNOSIS | SEROUS CARCINOMA | RISK | PROGESTERONE-RECEPTOR | GROWTH-FACTOR | ESTROGEN-RECEPTOR | EPITHELIAL OVARIAN | Receptors, Estrogen - metabolism | Prognosis | Follow-Up Studies | Adenocarcinoma, Mucinous - pathology | Tissue Array Analysis | Adenocarcinoma, Clear Cell - mortality | Humans | Middle Aged | Cystadenocarcinoma, Serous - metabolism | Ovarian Neoplasms - pathology | Ovarian Neoplasms - mortality | Cystadenocarcinoma, Serous - pathology | Case-Control Studies | Immunoenzyme Techniques | Carcinoma, Endometrioid - metabolism | Receptors, Progesterone - metabolism | Neoplasm Grading | Biomarkers, Tumor - metabolism | Female | Ovarian Neoplasms - metabolism | Ovary - metabolism | Ovary - pathology | Adenocarcinoma, Clear Cell - metabolism | Neoplasm Invasiveness | Survival Rate | Adenocarcinoma, Mucinous - mortality | Carcinoma, Endometrioid - mortality | Adenocarcinoma, Mucinous - metabolism | Cystadenocarcinoma, Serous - mortality | Adenocarcinoma, Clear Cell - pathology | Neoplasm Staging | Carcinoma, Endometrioid - pathology | Consortia | Analysis | Oncology, Experimental | Hormones | Research | Ovarian cancer | Cancer
Journal Article
International Journal of Gynecological Pathology, ISSN 0277-1691, 07/2018, Volume 37, Issue 4, pp. 349 - 355
Of the subtypes of extracardiac rhabdomyoma, genital rhabdomyoma is most uncommon and is occasionally classified as fetal rhabdomyoma due to morphologic...
Vagina | Vulva | Cervix | Rhabdomyoma | CELL CARCINOMA SYNDROME | PATHOLOGY | TUMORS | CARDIAC RHABDOMYOMA | OBSTETRICS & GYNECOLOGY | WOMEN | FETAL RHABDOMYOMA | GENE | GORLIN SYNDROME | Oligonucleotide Array Sequence Analysis | Humans | Middle Aged | Rhabdomyoma - genetics | Loss of Heterozygosity | Genitalia, Female - pathology | DNA Copy Number Variations | Adult | Female | Aged | Genital Neoplasms, Female - pathology | Genital Neoplasms, Female - genetics | Rhabdomyoma - pathology | Care and treatment | Development and progression | Genetic aspects | Single nucleotide polymorphisms | Gene expression | Health aspects | Genital diseases, Female
Vagina | Vulva | Cervix | Rhabdomyoma | CELL CARCINOMA SYNDROME | PATHOLOGY | TUMORS | CARDIAC RHABDOMYOMA | OBSTETRICS & GYNECOLOGY | WOMEN | FETAL RHABDOMYOMA | GENE | GORLIN SYNDROME | Oligonucleotide Array Sequence Analysis | Humans | Middle Aged | Rhabdomyoma - genetics | Loss of Heterozygosity | Genitalia, Female - pathology | DNA Copy Number Variations | Adult | Female | Aged | Genital Neoplasms, Female - pathology | Genital Neoplasms, Female - genetics | Rhabdomyoma - pathology | Care and treatment | Development and progression | Genetic aspects | Single nucleotide polymorphisms | Gene expression | Health aspects | Genital diseases, Female
Journal Article
Journal of Surgical Oncology, ISSN 0022-4790, 12/2016, Volume 114, Issue 7, pp. 879 - 883
Journal Article
International Journal of Gynecological Pathology, ISSN 0277-1691, 09/2015, Volume 34, Issue 5, pp. 437 - 444
Hemangiomas of the ovary are rare with a majority described as individual reports of unusual clinical presentations or morphologic findings. Both the expected...
Ovary | EWSR1 | Hemangioma | PSEUDO-MEIGS-SYNDROME | ASCITES | FLORID VASCULAR PROLIFERATION | PATHOLOGY | TUMORS | OBSTETRICS & GYNECOLOGY | ELEVATED CA-125 | MATURE CYSTIC TERATOMA | STROMAL LUTEOMA | ANGIOSARCOMA | Calmodulin-Binding Proteins - genetics | Immunohistochemistry | RNA-Binding Proteins - genetics | Antigens, CD34 - analysis | Hemangioma - pathology | Humans | Middle Aged | Ovarian Neoplasms - pathology | Microfilament Proteins - analysis | Platelet Endothelial Cell Adhesion Molecule-1 - analysis | In Situ Hybridization, Fluorescence | Receptors, Estrogen - analysis | Ovarian Neoplasms - genetics | Receptors, Progesterone - analysis | Receptors, Cytoplasmic and Nuclear - analysis | Gene Rearrangement | Aged, 80 and over | Female | Aged | Hemangioma - genetics | RNA-Binding Protein EWS
Ovary | EWSR1 | Hemangioma | PSEUDO-MEIGS-SYNDROME | ASCITES | FLORID VASCULAR PROLIFERATION | PATHOLOGY | TUMORS | OBSTETRICS & GYNECOLOGY | ELEVATED CA-125 | MATURE CYSTIC TERATOMA | STROMAL LUTEOMA | ANGIOSARCOMA | Calmodulin-Binding Proteins - genetics | Immunohistochemistry | RNA-Binding Proteins - genetics | Antigens, CD34 - analysis | Hemangioma - pathology | Humans | Middle Aged | Ovarian Neoplasms - pathology | Microfilament Proteins - analysis | Platelet Endothelial Cell Adhesion Molecule-1 - analysis | In Situ Hybridization, Fluorescence | Receptors, Estrogen - analysis | Ovarian Neoplasms - genetics | Receptors, Progesterone - analysis | Receptors, Cytoplasmic and Nuclear - analysis | Gene Rearrangement | Aged, 80 and over | Female | Aged | Hemangioma - genetics | RNA-Binding Protein EWS
Journal Article
International Journal of Gynecological Cancer, ISSN 1048-891X, 02/2009, Volume 19, Issue 2, pp. 253 - 256
Our objective was to investigate recurrence patterns and conduct an outcome analysis of patients with endometrial stromal sarcoma (ESS).A retrospective review...
Lymphadenectomy | Surgical management | Endometrial stromal sarcoma | LYMPH-NODE METASTASES | UTERINE-SARCOMA | ONCOLOGY | UTERUS | LETROZOLE | GRADE | TUMORS | OBSTETRICS & GYNECOLOGY | Lymph Node Excision | Humans | Middle Aged | Neoplasm Recurrence, Local | Lymphatic Metastasis | Hysterectomy | Sarcoma, Endometrial Stromal - surgery | Endometrial Neoplasms - secondary | Endometrial Neoplasms - surgery | Survival Analysis | Female | Retrospective Studies | Sarcoma, Endometrial Stromal - secondary
Lymphadenectomy | Surgical management | Endometrial stromal sarcoma | LYMPH-NODE METASTASES | UTERINE-SARCOMA | ONCOLOGY | UTERUS | LETROZOLE | GRADE | TUMORS | OBSTETRICS & GYNECOLOGY | Lymph Node Excision | Humans | Middle Aged | Neoplasm Recurrence, Local | Lymphatic Metastasis | Hysterectomy | Sarcoma, Endometrial Stromal - surgery | Endometrial Neoplasms - secondary | Endometrial Neoplasms - surgery | Survival Analysis | Female | Retrospective Studies | Sarcoma, Endometrial Stromal - secondary
Journal Article
Nature Communications, ISSN 2041-1723, 2013, Volume 4, Issue 1, p. 1628
HNF1B is overexpressed in clear cell epithelial ovarian cancer, and we observed epigenetic silencing in serous epithelial ovarian cancer, leading us to...
COMMON VARIANTS | RISK | CLEAR-CELL CARCINOMA | LOCUS | MULTIDISCIPLINARY SCIENCES | GENOME-WIDE ASSOCIATION | Ovarian Neoplasms - genetics | Promoter Regions, Genetic | DNA Methylation | Genetic Predisposition to Disease | Epigenesis, Genetic | Humans | Female | Gene Expression Profiling | Polymorphism, Single Nucleotide | Hepatocyte Nuclear Factor 1-beta - genetics
COMMON VARIANTS | RISK | CLEAR-CELL CARCINOMA | LOCUS | MULTIDISCIPLINARY SCIENCES | GENOME-WIDE ASSOCIATION | Ovarian Neoplasms - genetics | Promoter Regions, Genetic | DNA Methylation | Genetic Predisposition to Disease | Epigenesis, Genetic | Humans | Female | Gene Expression Profiling | Polymorphism, Single Nucleotide | Hepatocyte Nuclear Factor 1-beta - genetics
Journal Article
Pathology, ISSN 0031-3025, 2014, Volume 46, pp. S86 - S87
Journal Article
Clinical Cancer Research, ISSN 1078-0432, 08/2017, Volume 23, Issue 15, pp. 4077 - 4085
Purpose: Here we assess whether molecular subtyping identifies biological features of tumors that correlate with survival and surgical outcomes of high-grade...
MOLECULAR SUBTYPES | BREAST-CANCER | REPAIR | MICROARRAY | SIGNATURES | ONCOLOGY | CARCINOMA | Neoplasm, Residual - pathology | Prognosis | Neoplasm, Residual - surgery | Humans | Middle Aged | Gene Expression Regulation, Neoplastic | Ovarian Neoplasms - pathology | Cystadenocarcinoma, Serous - genetics | Cystadenocarcinoma, Serous - pathology | Cystadenocarcinoma, Serous - drug therapy | Ovarian Neoplasms - genetics | Neoplasm Grading | Aged, 80 and over | Adult | Female | Neoadjuvant Therapy | Neoplasm Proteins - genetics | Ovarian Neoplasms - drug therapy | Treatment Outcome | Cystadenocarcinoma, Serous - surgery | Neoplasm, Residual - genetics | Disease-Free Survival | Neoplasm, Residual - drug therapy | Aged | Ovarian Neoplasms - surgery | Surgical outcomes | Ovarian carcinoma | Mesenchyme | Gene expression | Clustering | Survival | Patients | Ovarian cancer | Experimental design | Quality | Surgery | Tumors | Cancer | prognostic | molecular subtypes | consensus clustering | ovarian cancer | surgical outcome
MOLECULAR SUBTYPES | BREAST-CANCER | REPAIR | MICROARRAY | SIGNATURES | ONCOLOGY | CARCINOMA | Neoplasm, Residual - pathology | Prognosis | Neoplasm, Residual - surgery | Humans | Middle Aged | Gene Expression Regulation, Neoplastic | Ovarian Neoplasms - pathology | Cystadenocarcinoma, Serous - genetics | Cystadenocarcinoma, Serous - pathology | Cystadenocarcinoma, Serous - drug therapy | Ovarian Neoplasms - genetics | Neoplasm Grading | Aged, 80 and over | Adult | Female | Neoadjuvant Therapy | Neoplasm Proteins - genetics | Ovarian Neoplasms - drug therapy | Treatment Outcome | Cystadenocarcinoma, Serous - surgery | Neoplasm, Residual - genetics | Disease-Free Survival | Neoplasm, Residual - drug therapy | Aged | Ovarian Neoplasms - surgery | Surgical outcomes | Ovarian carcinoma | Mesenchyme | Gene expression | Clustering | Survival | Patients | Ovarian cancer | Experimental design | Quality | Surgery | Tumors | Cancer | prognostic | molecular subtypes | consensus clustering | ovarian cancer | surgical outcome
Journal Article
Gynecologic Oncology, ISSN 0090-8258, 2007, Volume 108, Issue 3, pp. 619 - 626
Abstract Objectives. Folate receptor α (FRα) is a folate-binding protein overexpressed on ovarian and several other epithelial malignancies that can be used as...
Hematology, Oncology and Palliative Medicine | Obstetrics and Gynecology | Folate receptor | Ovarian cancer | 5-METHYLTETRAHYDROFOLATE | VIVO | ovarian cancer | BINDING-PROTEIN | folate receptor | CELL-GROWTH | OBSTETRICS & GYNECOLOGY | BREAST-CANCER | IN-VITRO | ONCOLOGY | TISSUES | IMAGING AGENTS | EXPRESSION | CARCINOMA | Immunohistochemistry | Folate Receptors, GPI-Anchored | Adenocarcinoma, Mucinous - pathology | Adenocarcinoma, Clear Cell - mortality | Humans | Middle Aged | Cystadenocarcinoma, Serous - metabolism | Gene Expression Regulation, Neoplastic | Ovarian Neoplasms - pathology | Neoplasm Recurrence, Local - drug therapy | Cystadenocarcinoma, Serous - genetics | Ovarian Neoplasms - mortality | Cystadenocarcinoma, Serous - pathology | Neoplasm Recurrence, Local - mortality | Cystadenocarcinoma, Serous - drug therapy | Carcinoma, Endometrioid - metabolism | Neoplasm Recurrence, Local - pathology | Ovarian Neoplasms - genetics | Neoplasm Metastasis | Female | Ovarian Neoplasms - metabolism | Retrospective Studies | Adenocarcinoma, Mucinous - drug therapy | Ovarian Neoplasms - drug therapy | Carcinoma, Endometrioid - genetics | Neoplasm Recurrence, Local - metabolism | Adenocarcinoma, Clear Cell - metabolism | Medical Records | Receptors, Cell Surface - metabolism | Minnesota | Carcinoma, Endometrioid - drug therapy | Adenocarcinoma, Mucinous - mortality | Carrier Proteins - genetics | Disease-Free Survival | Carrier Proteins - metabolism | Carcinoma, Endometrioid - mortality | Adenocarcinoma, Mucinous - metabolism | Survival Analysis | Cystadenocarcinoma, Serous - mortality | Neoplasm Recurrence, Local - genetics | Adenocarcinoma, Clear Cell - pathology | Adenocarcinoma, Mucinous - genetics | Adenocarcinoma, Clear Cell - genetics | Carcinoma, Endometrioid - pathology | Adenocarcinoma, Clear Cell - drug therapy | Receptors, Cell Surface - genetics | Folic acid
Hematology, Oncology and Palliative Medicine | Obstetrics and Gynecology | Folate receptor | Ovarian cancer | 5-METHYLTETRAHYDROFOLATE | VIVO | ovarian cancer | BINDING-PROTEIN | folate receptor | CELL-GROWTH | OBSTETRICS & GYNECOLOGY | BREAST-CANCER | IN-VITRO | ONCOLOGY | TISSUES | IMAGING AGENTS | EXPRESSION | CARCINOMA | Immunohistochemistry | Folate Receptors, GPI-Anchored | Adenocarcinoma, Mucinous - pathology | Adenocarcinoma, Clear Cell - mortality | Humans | Middle Aged | Cystadenocarcinoma, Serous - metabolism | Gene Expression Regulation, Neoplastic | Ovarian Neoplasms - pathology | Neoplasm Recurrence, Local - drug therapy | Cystadenocarcinoma, Serous - genetics | Ovarian Neoplasms - mortality | Cystadenocarcinoma, Serous - pathology | Neoplasm Recurrence, Local - mortality | Cystadenocarcinoma, Serous - drug therapy | Carcinoma, Endometrioid - metabolism | Neoplasm Recurrence, Local - pathology | Ovarian Neoplasms - genetics | Neoplasm Metastasis | Female | Ovarian Neoplasms - metabolism | Retrospective Studies | Adenocarcinoma, Mucinous - drug therapy | Ovarian Neoplasms - drug therapy | Carcinoma, Endometrioid - genetics | Neoplasm Recurrence, Local - metabolism | Adenocarcinoma, Clear Cell - metabolism | Medical Records | Receptors, Cell Surface - metabolism | Minnesota | Carcinoma, Endometrioid - drug therapy | Adenocarcinoma, Mucinous - mortality | Carrier Proteins - genetics | Disease-Free Survival | Carrier Proteins - metabolism | Carcinoma, Endometrioid - mortality | Adenocarcinoma, Mucinous - metabolism | Survival Analysis | Cystadenocarcinoma, Serous - mortality | Neoplasm Recurrence, Local - genetics | Adenocarcinoma, Clear Cell - pathology | Adenocarcinoma, Mucinous - genetics | Adenocarcinoma, Clear Cell - genetics | Carcinoma, Endometrioid - pathology | Adenocarcinoma, Clear Cell - drug therapy | Receptors, Cell Surface - genetics | Folic acid
Journal Article
Gynecologic Oncology, ISSN 0090-8258, 2013, Volume 132, Issue 1, pp. 38 - 43
Abstract Objective To prospectively define the prevalence of lymph node metastasis (LNM) in at risk endometrial cancer (EC). Methods From 2004 to 2008, frozen...
Hematology, Oncology and Palliative Medicine | Obstetrics and Gynecology | Lymph node metastasis | Lymphadenectomy | Endometrial cancer | Risk factors | COST | MORBIDITY | ONCOLOGY | RISK | CARCINOMA | OBSTETRICS & GYNECOLOGY | Lymph Node Excision | Lymph Nodes - pathology | Prospective Studies | Humans | Endometrial Neoplasms - surgery | Endometrial Neoplasms - pathology | Female | Lymphatic Metastasis | Metastasis | Analysis | Cancer | Prevalence studies (Epidemiology) | endometrial cancer | risk factors | lymphadenectomy
Hematology, Oncology and Palliative Medicine | Obstetrics and Gynecology | Lymph node metastasis | Lymphadenectomy | Endometrial cancer | Risk factors | COST | MORBIDITY | ONCOLOGY | RISK | CARCINOMA | OBSTETRICS & GYNECOLOGY | Lymph Node Excision | Lymph Nodes - pathology | Prospective Studies | Humans | Endometrial Neoplasms - surgery | Endometrial Neoplasms - pathology | Female | Lymphatic Metastasis | Metastasis | Analysis | Cancer | Prevalence studies (Epidemiology) | endometrial cancer | risk factors | lymphadenectomy
Journal Article
Modern Pathology, ISSN 0893-3952, 04/2008, Volume 21, Issue 4, pp. 455 - 463
Non-Hodgkin lymphomas of the breast are rare, encompassing approximately 0.04-0.5% of all malignant breast tumors, and the vast majority are B-cell lymphomas....
Breast implant | Saline | Anaplastic large-cell lymphoma | Silicone | Primary lymphoma of breast | silicone | saline | primary lymphoma of breast | INVOLVEMENT | CLUSTERIN | PATHOLOGY | SEZARY-SYNDROME | anaplastic large-cell lymphoma | SILICONE GRANULOMAS | HUMAN ADJUVANT DISEASE | INFLAMMATION | breast implant | PCR | Immunohistochemistry | Seroma - pathology | Breast Implants - adverse effects | Humans | Middle Aged | Breast Neoplasms - etiology | Immunophenotyping | Lymphoma, Large-Cell, Anaplastic - etiology | Breast Neoplasms - metabolism | Breast Neoplasms - therapy | Seroma - etiology | Seroma - metabolism | Breast Neoplasms - pathology | Mastectomy | Adult | Female | Lymphoma, Large-Cell, Anaplastic - pathology | Lymphoma, Large-Cell, Anaplastic - metabolism
Breast implant | Saline | Anaplastic large-cell lymphoma | Silicone | Primary lymphoma of breast | silicone | saline | primary lymphoma of breast | INVOLVEMENT | CLUSTERIN | PATHOLOGY | SEZARY-SYNDROME | anaplastic large-cell lymphoma | SILICONE GRANULOMAS | HUMAN ADJUVANT DISEASE | INFLAMMATION | breast implant | PCR | Immunohistochemistry | Seroma - pathology | Breast Implants - adverse effects | Humans | Middle Aged | Breast Neoplasms - etiology | Immunophenotyping | Lymphoma, Large-Cell, Anaplastic - etiology | Breast Neoplasms - metabolism | Breast Neoplasms - therapy | Seroma - etiology | Seroma - metabolism | Breast Neoplasms - pathology | Mastectomy | Adult | Female | Lymphoma, Large-Cell, Anaplastic - pathology | Lymphoma, Large-Cell, Anaplastic - metabolism
Journal Article
International Journal of Gynecological Pathology, ISSN 0277-1691, 11/2012, Volume 31, Issue 6, pp. 538 - 540
We report the first case of a combined adult granulosa cell tumor and endometrioid carcinoma collision tumor occurring in an ovary.
Adult granulosa cell tumor | Collision tumor | Ovary | Endometrioid carcinoma | NEOPLASM | CYSTADENOMA | INHIBIN | HETEROLOGOUS MUCINOUS ELEMENTS | PATHOLOGY | OBSTETRICS & GYNECOLOGY | Ovarian Neoplasms - chemistry | Carcinoma, Endometrioid - chemistry | Humans | Middle Aged | Ovarian Neoplasms - pathology | Female | Granulosa Cell Tumor - chemistry | Granulosa Cell Tumor - pathology | Keratin-7 - analysis | Carcinoma, Endometrioid - pathology
Adult granulosa cell tumor | Collision tumor | Ovary | Endometrioid carcinoma | NEOPLASM | CYSTADENOMA | INHIBIN | HETEROLOGOUS MUCINOUS ELEMENTS | PATHOLOGY | OBSTETRICS & GYNECOLOGY | Ovarian Neoplasms - chemistry | Carcinoma, Endometrioid - chemistry | Humans | Middle Aged | Ovarian Neoplasms - pathology | Female | Granulosa Cell Tumor - chemistry | Granulosa Cell Tumor - pathology | Keratin-7 - analysis | Carcinoma, Endometrioid - pathology
Journal Article